In subsequent studies, evaluation of tumors by TSP1 immunostaining indicated that its expression was increased in the tumors re-sensitized to tamoxifen [204], thus indicating an interplay of TSP1, CD47 expression, and metabolic regulation on cancer therapy sensitivity. This evidence concerns the gene CD47 and cancer.